Topic
Withania somnifera
About: Withania somnifera is a research topic. Over the lifetime, 2116 publications have been published within this topic receiving 43404 citations. The topic is also known as: Ashwaganda & Indian ginseng.
Papers published on a yearly basis
Papers
More filters
TL;DR: In this paper, the up-regulation of squalene synthase in withanolides biosynthesis pathway in hairy roots was investigated in the presence of Indian ginseng, Withania somnifera (L) Dunal (Solanaceae) is extensively used in ayurvedic and other traditional medicines.
8 citations
TL;DR: In this article, the changes of dynamics of squalene content in different tissues (leaves, stems, roots and berries) of Ashwagandha (Withania somnifera L. Dunal) was analyzed at different growth phases via high-performance liquid chromatography (HPLC).
8 citations
01 Jan 2017
TL;DR: The article provides information on the mechanisms involved in neuroprotective ability of WS in preventing various neurodegenerative conditions.
Abstract: Withania somnifera, commonly known as Ashwagandha, is a herb used in the Indian Ayurvedic medical system for centuries for its health benefits in wide range of conditions. It has been documented to enhance the functions of the nervous system and improves cognition. Medicinal properties of Withania somnifera are primarily attributed to the presence of active constituents known as withanolides. The multimodal beneficial effects of WS and its constituents stem from its property to act as an anti-oxidant, anti-inflammatory, anti-cancer, hemopoietic and rejuvenating agent. WS has been shown to have beneficial role in many neurological conditions that include Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, anxiety disorders, cerebral ischemia. However, the mechanisms involved in the beneficial effects of WS have not been well understood. The article provides information on the mechanisms involved in neuroprotective ability of WS in preventing various neurodegenerative conditions.
8 citations
TL;DR: Evaluating the analgesic effect and tolerability of single oral dose of standardized aqueous extract of Withania somnifera using Hot Air Pain model in healthy human volunteers found both drugs were well tolerated.
Abstract: Pain is the most prevalent health care problem. Most analgesics available today have good analgesic activity but are associated with lot of side effects. So analgesics with minimal side effects are required which can be evaluated by hot air pain model in healthy volunteers. Withani somnifera with various properties due to its active constituents-withanolides is widely used in Ayurvedic medicine. This study was done to evaluate the analgesic effect and tolerability of single oral dose (1000mg) of standardized aqueous extract of Withania somnifera using Hot Air Pain model in healthy human volunteers as per ICH GCP Guidelines after taking written informed consent to protocol approved by IEC. Subjects were randomised to receive either single oral dose of 1000mg standardized aqueous extract of Withania somnifera or identical placebo in a double blind manner. Mean Pain Threshold Time at baseline and 3hrs after drug administration were noted. Washout period of 10-14 days was given for cross-over between the two treatments. Safety assessments were conducted before and at end of study Total twelve subjects were enrolled. Mean Pain Threshold Time with Withania somnifera increased from 43.99±6.79 to 49.89±7.07 sec (p<0.05). No significant change was observed with placebo. Both drugs were well tolerated.
8 citations
TL;DR: The investigation discloses potent and prudent therapeutic potential of a new formulation using standardized fraction of anew variety of Withania somnifera (NMITLI118RT+) for brain function restoration and protection from neurological failures.
Abstract: Withania somnifera Dunal (Ashwagandha), is an Indian medicinal plant with significant pharmacological properties. Withanolides (steroidal lactones) are the chief constituents potentially responsible for its activity. Some of its chemotypes includes NMITLI-101, NMITLI-118, NMITLI-128. The present work elaborates the optimization and development of a ready to fill capsule powder blend (NMITLI118RT+CFM) for efficient delivery of NMITLI118RT+ (a standardized extract of a new chemotype of Withania somnifera Dunal) and to investigate their protective effects against cerebral stroke in rats. NMITLI118RT+CFM was prepared by solid liquid compacting technique and filled into capsules; it was characterized on the basis of loss on drying, flow properties, IR, disintegration time, weight variation, content uniformity and DSC analysis. NMITLI118RT+ and NMITLI118RT+CFM were evaluated for biological activity utilizing middle cerebral artery occlusion model in rats. NMITLI118RT+CFM was found to be pharmaceutically acceptable. Results showed that NMITLI118RT+ and NMITLI118RT+CFM possess significant neuroprotective activity against cerebral ischemia at 50 mg kg−1 in rats. NMITLI118RT+ and its pharmaceutical compositions exhibit sufficient biological promise for management of cerebral stroke. The investigation discloses potent and prudent therapeutic potential of a new formulation using standardized fraction of a new variety of Withania somnifera (NMITLI118RT+) for brain function restoration and protection from neurological failures.
8 citations